Fig. 6From: The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysisThe forest plot shows the correlation between Evusheld administration as prophylaxis and the mortality rate of COVID-19 infections in double-arm subgroupBack to article page